BRCA1 and breast cancer: First, although we observed significantly lower left ventricular systolic function in breast cancer survivors treated with doxorubicin compared to those without doxorubicin exposure, we did not find differences in age-adjusted estimates of echocardiography-derived measures of systolic or diastolic dysfunction according to germline BRCA1/2 mutation status.